Skip to content
ESPT
MARKETS / BALCAO / Health care / Pharmaceuticals / ELTP
BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Elite Pharmaceuticals Inc. ELTP

16 fiscal years on record · USD · FY2025 reported · SEC filings only
$148.9M
▲ 77.1% YoY
$44.9M
$22.8M
▲ 291.4% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company principally engaged in the development and manufacture of oral, controlled-release products, and the manufacture of generic pharmaceuticals. It occupies manufacturing, warehouse, laboratory, and office space at 135, 144, and 165 Ludlow Avenue in Northvale, New Jersey, a facility that operates under Current Good Manufacturing Practice and is registered with the U.S. Drug Enforcement Agency for research, development, and manufacturing. As of June 25, 2026, it had 65 full-time employees, engaged in operations, administration, research, and development. As of March 31, 2026, the Company operated in a single operating and reportable segment, its ANDA segment. For the year ended March 31, 2026, revenue from its ANDA segment was $148.9 million. Elite Pharmaceuticals, Inc. was incorporated on October 1, 1997 under the laws of the State of Delaware, and was reincorporated under the laws of the State of Nevada on January 5, 2012.

Written from the business description in ELITE PHARMACEUTICALS INC /NV/'s annual report to the U.S. Securities and Exchange Commission, filed 29 June 2026. Every sentence was checked against that document before publication.

Growth

USD 148.9M
Revenue, FY2025 · full 16-year series below
Revenue $M Net income $M
FY2025 · Revenue 148.9 · Net income 44.9
100M200M-15M-30M
201020132016201920222025
Compound annual growth
+63.3%
+42.4%
+28.1%
+26.7%
+132.7%
+54.6%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +42.4% a year over the five years to FY2025 — but profit grew faster: net income at +54.6%.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

30 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 33.0% · Net 30.1%
50%100%-500%
201020172025
ROE
FY2025 · ROE 58.9%
20%40%-10%-20%
201020172025
Three returns, three denominators.
Gross margin50.4%
Operating margin33.0%
Net margin30.1%
EBITDAUSD 50.2M

Each USD of equity produced 59 cents of profit this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 22.8
10M20M-2M-3M
201020172025
Dividends paid·
Net buybacks·
Share of profit·
Consecutive raises·

Total assetsUSD 138.3M
EquityUSD 98.9M
CashUSD 30.3M
Current ratio6.45×

Equity funds 72% of total assets.

The 16-year record

16 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
ELTP, 16-year financial record
Metric 2025202420232022202120202019201820172016201520142013201220112010
Revenue $B0.10.10.10.00.00.00.00.00.00.00.00.00.00.00.00.0
Operating income $B0.00.00.00.00.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B0.10.00.00.00.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B0.00.0−0.00.0−0.0◌◌−0.0−0.0−0.0−0.0−0.0−0.0◌◌◌
Net income $B0.0−0.00.00.00.00.0−0.0−0.0−0.00.0−0.00.0−0.00.0−0.0−0.0
Free cash flow $B0.00.0−0.0−0.00.0◌◌◌◌◌◌◌◌◌◌◌
EPS, diluted $0.030.000.020.000.010.000.00−0.01−0.010.01−0.010.02−0.210.00−0.06−0.14
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend————————————————
ROE %58.9−7.846.513.143.038.0——−24.3———————
Shares out B1.081.071.070.001.011.010.840.820.800.930.710.630.560.370.330.18

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

MCK · COR · CAH · JNJ · HCA · LLY
Provenance

Company facts, as filed

How we verify · 0 failures in 76 reconciliationsAUDITED

Reconciled in 16 of the 16 fiscal years we could check. Six checks were skipped: the balance sheet is not tagged before 2010. Four checks were skipped: the share count is not tagged before 2011. Three checks were skipped: revenue is not tagged before 2010.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onOTC market
Incorporated inNew Jersey
Fiscal year endsMarch 31
SEC categorysmaller reporting company
Data on record since2009

Share this section

Download image